chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient fully vaccinated (J&J), but not boosted, admitted to the hospital on 7/6/22 (after Dose 1) with COVID-19 and associated hypoxia. Patient was discharged on 7/12/22.
Fever 103.2, extreme fussiness and inconsolable crying for 48 hours.
Patient developed edema and redness to about 70% of her upper left arm the next day, 01/18/2021, in the morning is when she noticed and it worsened for several days. By the seventh day, the swelling and redness started to improve. She did experience intense itching especially around the injection site. She did take Benadryl around day seven or eight for the itching. She did have muscle soreness for about 1 - 2 days that resolved. She did not have any further pain despite the redness and swelling. She had no fever, chills, body aches. She did not have any wheezing or SOB. Overall, she reports that besides the itching she felt good.
swelling in the area of both my left and right supraclavicular nodes; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 02Mar2021 10:30 (Lot number: EP7534) at the age of 62 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "High blood pressure - controlled with medication" (unspecified if ongoing), notes: Verbatim: High blood pressure - controlled with medication. Concomitant medication(s) included: LOSARTAN; AMLODIPINE. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 25Mar2021 14:00, outcome "not recovered", described as "swelling in the area of both my left and right supraclavicular nodes". The event "swelling in the area of both my left and right supraclavicular nodes" was evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of lymphadenopathy.  Additional Information: Patient did not receive other vaccine in four weeks. Patient received Losartan, Amlodipine medications in two weeks. Somewhere between his 1st and 2nd dose patient noticed a significant swelling in the area of both his left and right supraclavicular nodes. At first he was not sure what the significance was as he had no pain. The swelling continued and he saw his primary doctor in August. He was not sure what was happening so he ordered an ultrasound, bloodwork and a lung xray to rule out lymphoma and explained to him the timing of when it happened and we both suspected it could be from the vaccines. All of his tests showed nothing remarkable or concerning. He was put on Amoxicillin and Prednisone. As he was sending this information he still have the same large swelling in both nodes. Nothing has changed in almost 10 months. he contacted the CDC with this same information but was never given a response. he would like to know what possible recourse as to what type of specialist to see for any type of remedy for his situation. Patient received AE treatment of Ultrasound, bloodwork, x-ray, antibiotics, prednisone. Patient did not had covid prior vaccination. Patient had tested covid post vaccination. patient had none known allergies.  No follow-up attempts are possible. No further information is expected.
After having the pneumonia shot at 9 AM, and later fasting for blood work, and late breakfast, I began to feel bad, took a TYLENOL and went to bed. I woke about 4 PM and discovered the elbow, very red, and feverish. I called my doctor who recommended a trip to the ER where I was prescribed medication to control adverse condition. The medicine was Hydroxyzine HCL 25 mg. The swelling, redness, and fever continued to move on past the elbow to the wrist area. It took a week for the swelling to subside. I also used ice packs and TYLENOL in addition to the ATARAX. This was my second pneumonia shot.
diagnosed with COVID on 01Oct; diagnosed with COVID on 01Oct; This is a spontaneous report from a contactable consumer (patient, reported for self). A patient of an unspecified age and gender received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, lot/batch number was not reported) via an unspecified route of administration on an unspecified date as dose 2, single and first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, lot/batch number was not reported) via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunisation. The patient's medical history included rheumatoid arthritis. The patient's concomitant medications included Methotrexate 17.5 mg QW (weekly) and abatacept (ORENCIA) Clickject QW (weekly), both for rheumatoid arthritis. On 01Oct2021, the patient got diagnosed with COVID. The patient underwent lab test and procedure included COVID (SARS-CoV-2 test): diagnosed with covid on 01Oct2021. Event took place after use of product. The outcome of events was unknown.  The lot number for the vaccine, [BNT162B2] was not provided and would be requested during follow-up.
Pt reports that beginning approximately 1 week after vaccination in May she began to experience a sensation in bilateral deltoids that is best described as a pins and needles sensation. This sensation has manifested approximately once every 3-4 weeks, and lasts for approximately 1-2 minutes.
This study case was received from the investigator on 12 November 2012. A 19-year-old male subject received the following vaccinations: On 01 August 2012 an injection of ACAM2000 (lot number not reported), on 30 July 2012 an injection of ANTHRAX (manufacturer and lot number not reported), and an injection of TWINRIX (manufacturer and lot number not reported). The subject had no significant medical history. On 31 August 2012, the subject had an abnormal troponin I of 00.67 and a normal echocardiogram. On 30 August 2012, the subject was diagnosed with non-specific myocarditis. The outcome was not reported. Additional information will be requested from the investigator. Note: There is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study. Documents held by sender: None.
Approximately 3-4 minutes after receiving vaccine, the patient lost consciousness and fell face first on floor.  The pharmacist on duty (myself) immediately evaluated the patient who was unresponsive and EMS was called. The patient was red/purple in the face, gasping for air and having difficulty breathing, and foaming at the mouth.  Epinephrine 0.3mL was administered IM and the patient responded immediately.  He was awake and alert until EMS arrive and transported him to the nearest hospital.
Starting 2 days after immunization SQ in (R) arm began experiencing tingling & burning in (L) arm radiating around elbow at times radiating to shoulder or down to hands (identified on 7/19/11 to clinician).
Flu like symptoms came on immediately lasted for three days.   Fairly moderate symptoms.     Afluria
Symptoms started approximately 1 week after vaccination, symptoms include fatigue, shortness of breath, water retention, swelling in feet and lower legs, high blood pressure, cough.
Based on additional information received on 22 May 2015, this case initially considered as non-serious was upgraded to serious: important medical event as gestational diabetes. Initial unsolicited pregnancy report received from a healthcare professional (Nurse) on 14 Oct 2014. A 36-year-old female patient, who had no current pregnancy history and concomitant medications were not reported, had received intradermal dose of FLUZONE ID (batch number- UT4993BA, expiry date-05 Jun 2015, dose number not reported) in left deltoid on 14 Oct 2014. The last menstrual period was not reported and estimated date of delivery was 30 Jan 2015. At the time of vaccination the patient was pregnant. At the time of this report, the patient had not experienced any adverse events. Documents held by sender: none. Follow up information received from a physician on 14 May 2015. Physician reported that he had not given flu vaccine to the patient and as per his knowledge patient had no problems. No new information reported. Documents held by sender: none. Follow-up information received from nurse on 14 May 2015 and additional information received on 22 May 2015. A 36-year-old female patient relevant ongoing illness status reported as gestational diabetes with pregnancy. The patient had no family history of congenital abnormality. Date of last menstrual periods was reported as mid of April 2014. The estimated date of delivery was reported as 30 January 2015, Caesarean section due to gestational diabetes. Patient had received treatment for infertility with first child, not with this pregnancy. Previously patient was pregnant with outcome as one live birth. The patient had one pre-term birth with 38 plus 6 weeks - gestational diabetes. Patient's did not had elective abortion, spontaneous abortion prior to 20 weeks gestation and fetal death (<20 weeks gestation). Patient had experienced just arm soreness for 2-3 days as a relevant non serious adverse event. During the current pregnancy the patient had experienced gestational diabetes; therefore caesarean section was performed at 38 weeks. The baby was healthy. Laboratory investigation includes, gender screening all result was negative, ultrasound result was negative and no abnormal test. Pregnancy complication was reported as gestational diabetes. Patient's pregnancy outcome date of delivery was reported with single number of children. It was reported that patient gave birth to single male without any complications of labor, having one minute APGAR score was 8 and five minute APGAR score was 9, delivery mode was C-sec, weeks of gestation was 38, birth weight was 3.91 kg (8 lb 10 oz) and no any congenital abnormality. List of documents held by sender: none.
Pt developed rash on 6/18, rash became more painful, started spreading and vesicles were forming by 6/19/20 when pt was evaluated in office. Pt was prescribed a course of Valtrex.
Vaccine given 10/17/16 at 1513/ Pt seen by doctor at 10/15/16 at 1015 AM. The person reported she felt last night that her tongue felt thick and throat was tight. This am  at 10:15 it was noted that she had a fever, rash, swollen, itchy, watery eyes and itchy neck. Sent to occupational medicine. Tx with BENADERYL.
migraine; Initial information received on 04-Nov-2021 regarding an unsolicited valid non-serious case received from a non-healthcare professional (under reference: US-SA-SAC20211111000298).  This case involves adult female patient who experienced migraine when received vaccine INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV].  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE (lot number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date the patient developed a non-serious migraine (unknown latency) following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE.  It was reported "I do not know when she received the shot, her age, etc., but she is internal, so you can find her in the system and contact her."  Laboratory details were not reported.  It was not reported if the patient received a corrective treatment for the event (migraine).  At the time of reporting, the outcome was unknown for the event (migraine).  There will be no information available on the batch number for this case.
Patient came in stating she had an adverse reaction to a Covid immunization. She said she had some redness and itching at the injection site, as well as heat in the area. She said it was not painful and has resolved with the exception of the itching. She is contacting her prescriber for more information.
Warmth at injection site; Swelling at injection site; Tenderness at Injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Warmth at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE PAIN (Tenderness at Injection site) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042B212A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included OMEPRAZOLE, OXYCODONE, DICYCLOMINE [DICYCLOVERINE], DICLOFENAC, CLOPIDOGREL, VENLAFAXINE, MAGNESIUM OXIDE, METFORMIN, LISINOPRIL, LEVETIRACETAM, PERPHENAZINE, MELATONIN, ROSUVASTATIN, INSULIN ASPART (NOVOLOG) and INSULIN GLARGINE (LANTUS) for an unknown indication.    On 14-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, the patient experienced VACCINATION SITE WARMTH (Warmth at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE PAIN (Tenderness at Injection site). At the time of the report, VACCINATION SITE WARMTH (Warmth at injection site), VACCINATION SITE SWELLING (Swelling at injection site) and VACCINATION SITE PAIN (Tenderness at Injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications were reported.
covid vaccine breakthrough case  dose 1 Moderna  3/13/21  002B21A dose 2 Moderna  4/10/21  025B21A dose 3 Moderna  11/24/21  012H21B
It is warm; Even up to the back of the shoulder to the neck is painful; Even up to the back of the shoulder to the neck is painful; Her whole arm is sore up to her neck and down the arm/It is very painful/it throbs; Last night she was up all night, every 3 hours; This is a spontaneous report from a contactable consumer (patient).  A 59-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (lot number EL1284, expiration date Apr2021), via an unspecified route of administration at left arm on 30Dec2020 09:30 at single dose for COVID-19 immunization, at a hospital. The vaccine was not administered at military facility. The patient's medical history included ongoing asthma from 2005 (diagnosed 15 years ago) and allergies. For asthma She has ProAir rescue inhaler to use as needed. Breo inhaler she uses at night. She has been on it for 2 years. She has been on different inhalers. Family medical history relevant to events was reported as none. Concomitant medication included montelukast sodium (SINGULAIR) from 2005 (had been on it probably 15 years) and ongoing at 10 mg, daily for allergies; fluticasone furoate, vilanterol trifenatate (BREO ELLIPTA) inhaler via resp Inhalation from 2018 (has been on it for 2 years), uses it at night, for asthma; and salbutamol sulfate (PROAIR HFA) rescue inhaler via resp Inhalation, to use as needed for asthma. The patient had no history of previous immunization with the Pfizer vaccine. For historical vaccine, the patient received Tetanus for immunization and had allergic to Tetanus, her arm swelled and she couldn't move it (which was kind of like this, but not as severe).  She didn't know the brand name for the tetanus vaccine she had reaction to. She didn't have NDC, lot, or expiry. It was 40 years ago. She had the reaction when she was 18 years old. There was no vaccine administered on same date of the Pfizer suspect, and tno vaccinations within 4 weeks prior to the Pfizer suspect. It was reported that last night (30Dec2020) she was up all night, every 3 hours. She was taking Advil. Her whole arm was sore up to her neck and down the arm. She had a nurse look at it this morning (31Dec2020) and it was not red. It was warm and it throbs. No rash. It was very painful. Even up to the back of the shoulder to the neck was painful. Her arm being sore and painful was ongoing at the time of report. She had been taking Advil. The pain had stayed the same even with the Advil. The events started probably between 14:00 and 14:30, it started off sore then became more painful. At the time of reporting, she was not at home and didn't have the bottle to provide NDC, lot, and expiry for Advil. She was taking some at the office, but that was in a travel bottle and didn't have the lot, expiry, and NDC. No emergency room or physician office visit. Relevant tests was none. The outcome of the events was unknown.
On 3-17-04 received DTaP Left Deltoid IM.  First noticed reddened, warm to touch, painful hard swelling at sight of injection on 3-18-04 in the evening.  White ring also noted per mother around the site of the injection inside the reddened area.  Mother reportely gave Benadryl doses and Tylenol.
Pt called and reported she had experienced fever (T max 100.6), myalgias, and sensation of "electric shocks" after vaccinations; pt reported symptoms were relieved by taking ASA and are now resolving.
Pt experienced full body rash with mild itching, head to toe, covering 90% of body surface area starting 3 days after injection that lasted for 6 total days. Pt used Benadryl during this time to treat symptoms which resolved with OTC self care. Pt has since seen her prescriber about the event.
02/16/2021 I woke up with a headache for two and had month uncontrollable chills on the first day, fever of 104 lasted three days. Very tired and mental fog for two months. I went to emergency room on 02/16/2021 was sent home with no testing and no prescriptions.
Information has been received from a registered nurse concerning a 7 year old male patient who on an unspecified date was vaccinated with 0.5ml dose of VARIVAX (Merck) (lot# not reported). On an unspecified date, the patient broke out with chickenpox. On an unspecified date the patient recovered from chickenpox. The patient sought unknown medical attention. Additional information has been requested. The patient's sibling also experienced chickenpox after receiving 0.5ml dose of VARIVAX (Merck) (WAES # 1009USA00557).
"electrical shot" all over body; This spontaneous case was reported by a consumer and describes the occurrence of   in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.            24Feb2021 Within 30 minutes after vaccination, Patient felt like an "electric shot" all over body.  Action taken with mRNA-1273 in response to the events was not Applicable.   Reporter did not allow further contact
The MMR went out of temperature to 55.4F and the manufacture said to not give it and we did before knowing it was not useable.
Rash - stated end of September - itchy red patches in right arm - area of vaccination.
Mostly sinus issues and in my chest not as much coughing as it was coughing up gunk, runny nose , congestion, sneezing.
Felt tingling in the left side of my face; felt tingling in my tongue and the left side of my face; My arm was also very sore; A spontaneous report was received from a consumer concerning a 66-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced facial paresthesia, tongue paraesthesia and vaccination site pain.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 12th Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot batch: unknown) intramuscularly for prophylaxis of COVID-19 infection.  On 12 Jan 2021, 15 seconds after the vaccination, the patient experienced the events in my tongue and the left side of my face, and her arm was also felt sore.  Treatment options included Benadryl.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events, experienced facial paresthesia, tongue paraesthesia and vaccination site pain, were unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
No additional AE reported; The patient had completed the HIB series and was due to receive polio but was inadvertently given PEDVAXHIB instead; The patient received an extra dose of PEDVAXHIB; This spontaneous report has been received from an office manager concerning a patient of unknown age and gender.  The patient's medical history, concurrent conditions, and concomitant therapies were not reported. The patient had completed the Haemophilus influenzae Type b (HIB) series.  On 30-SEP-2021, the patient was due to be vaccinated with polio vaccine but instead of this vaccine, he/she was inadvertently given an extra dose haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) 0.5 milliliter (lot number T030710 has been verified to be a valid lot number for haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB), expiration date reported and confirmed as 15-APR-2023) (route of administration and anatomical location were not provided) as prophylaxis (Wrong product administered) (Extra dose administered).  The reporter stated this was noticed when the parent got a call from school stating the vaccinations were not up to date and the records were checked. No additional adverse events (AE) were reported.
pt came in for well baby check during morning-given vax & mom returned to clinic afternoon stating pt had been screaming from 11AM to 2PM-brief nap for 5 mins;
Pt experienced swelling the size of a half dollar at injection site (left thigh) one day post vax.
client has facial flushing ; apparent on observation; RN obtained manual blood pressure 152/92. denies dyspnea, no history of allergies
Delayed  slow over 1 hour palms, feet, abdomen, chest, groin, armpits hives with itching, Indigestion, nausea, abdominal cramping, diarrhea, face itching. Took  Benadryl, Pepcid, singulair.  with moderate relief. Hives resolved, itching remains but improved.  Previous reaction after 2nd dose had to use Epi x3.
patient received 2nd dose of Shingrix on 31-Oct-2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) (batch number HT7XM, expiry date 15-SEP-2025) for prophylaxis.   Previously administered products included Shingrix (received the 1st dose of Shingrix in 2021).   On 31-OCT-2023, the patient received the 2nd dose of Shingrix. On 31-OCT-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient received 2nd dose of Shingrix on 31-Oct-2023). The outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK receipt date: 1-Nov-2023 The pharmacist did not want to provide patient's date of birth or initials. Did not consent to follow-up. The patient received 2nd dose of Shingrix later than the recommended interval, which led to lengthening of vaccine schedule.
Female received 2nd dose of Pfizer vaccination shot afterwards client states she feels dizzy and hot. I said busy and he is hot. Client was given water for hydration and cold ice packs were applied to face and neck. After two minutes of intervention client states she feels better and symptoms have discontinued.
Felt arm pain. Walked up the stairs, felt dizzy and fainted the evening after receiving vaccines. Woke up moments later and went to sleep. No treatment indicated. Acting as usual the following day - arm pain persists but no dizziness or other symptoms noted.
H/A, acute onset - temp 98.8F, B/P 120/60, muscle aches & leg cramps. Benadryl 50MG IM; Tylenol.
Headache the next day on the 30th when he woke up. He did not take anything for it and it went away on its own after a couple hours.